Product information and disease descriptionPlace of product in therapyDisease description
Definition and etiology
16 evidence topics · 12 sources
Blood pressure categories: 2025 AHA/ACC guideline
Treatment goal and controlled hypertension
Uncontrolled hypertension: definition in a US real-world prevalence study
Resistant hypertension definition: 2025 AHA/ACC guideline
Controlled, uncontrolled, and apparent treatment-resistant hypertension: AHA scientific statement
“RH is defined as the BP of a hypertensive patient that remains elevated above goal despite the concurrent use of 3 antihypertensive agents of different classes, commonly including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (angiotensin-converting enzyme [ACE] inhibitor or angiotensin receptor blocker [ARB]), and a diuretic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RH also includes patients whose BP achieves target values on ≥4 antihypertensive medications, a condition that has been referred to in the literature as controlled RH. Thus, the term RH refers to hypertension with both uncontrolled and controlled BP, depending on the number of antihypertensive agents used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The term apparent treatment RH (aTRH) is used when ≥1 of the following data elements are missing: medication dose, adherence, or out-of-office BP; thus, pseudoresistance cannot be excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistant hypertension definition: European guidelines
Etiology of primary hypertension: behavioral, environmental, hormonal, and genetic factors
Risk factors and demographic correlates of resistant hypertension
Secondary hypertension: settings and common causes
Primary aldosteronism: definition and adrenal subtypes
Primary aldosteronism prevalence by hypertension severity: 2025 AHA/ACC guideline
Primary aldosteronism in resistant hypertension: cohort studies with confirmatory testing
“Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension; corresponding adjusted prevalence estimates for biochemically overt primary aldosteronism were 11.3% (CI, 5.9% to 16.8%), 15.7% (CI, 8.6% to 22.9%), 21.6% (CI, 16.1% to 27.0%), and 22.0% (CI, 17.2% to 26.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 20 years, we studied 1616 patients with resistant hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis. Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this prospective study of 88 consecutive patients referred to a university clinic for resistant hypertension, we determined the 24-hour urinary aldosterone excretion during high dietary salt ingestion, baseline plasma renin activity, and plasma aldosterone in all subjects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen subjects (20%) were confirmed to have primary hyperaldosteronism. The prevalence of hyperaldosteronism was similar in black and white subjects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary aldosteronism in resistant hypertension: review estimates
“Primary aldosteronism (PA) is the leading cause of secondary hypertension, affecting at least 10% of all hypertensive patients and up to 25% of those with treatment-resistant hypertension, and is associated with markedly increased cardiovascular, metabolic, and kidney morbidity due to the systemic effects of excess aldosterone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone dysregulation in uncontrolled and resistant hypertension: company statement
Obstructive sleep apnea and renovascular disease in resistant hypertension
“Very high proportions (60%−84%) of individuals with RH have sleep apnea.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypertension accelerated or worsened by renal artery stenosis remains among the most common causes of RH, particularly in older age groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote